Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers

被引:0
|
作者
Malo, Sara [1 ]
Aguilar-Palacio, Isabel [1 ]
Feja, Cristina [1 ]
Menditto, Enrica [2 ]
Jesus Lallana, Maria [3 ]
Andrade, Elena [4 ,5 ]
Antonio Casasnovas, Jose [6 ]
Jose Rabanaque, Maria [1 ]
机构
[1] Univ Zaragoza, Dept Med Prevent & Salud Publ, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
[2] Univ Napoli Federico II, CIRFF, Naples, Italy
[3] IIS Aragon, Serv Aragones Salud, Zaragoza, Spain
[4] Univ Autonoma Madrid, Dept Med Prevent & Salud Publ, IdiPaz, Madrid, Spain
[5] CIBERESP, Madrid, Spain
[6] Univ Zaragoza, Dept Med Psiquiatria & Dermatol, Fdn Inst Invest Sanitaria Aragon IIS Aragon, Zaragoza, Spain
来源
REVISTA ESPANOLA DE CARDIOLOGIA | 2018年 / 71卷 / 01期
关键词
Discontinuation; Lipid-lowering drug; Pharmacoepidemiology; Medication; Measurement; Cardiovascular disease; Primary prevention; DENSITY-LIPOPROTEIN CHOLESTEROL; THERAPY; POPULATION; RISK;
D O I
10.1016/j.recesp.2017.03.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: The aim of this study was to assess patterns of treatment persistence in a cohort of male Spanish workers receiving statin therapy for primary prevention of cardiovascular disease. Methods: This descriptive study was conducted within the framework of the prospective longitudinal Aragon Workers' Health Study (N = 5400). Incident male statin users were identified based on data collected from the regional government's medication consumption information system. Patterns of treatment persistence with statins prescribed for primary cardiovascular disease prevention were assessed and, the relevance of potential predictors explored. Results: Among the 725 new statin users, less than one third remained persistent during the 1 year of follow-up. About 15% of nonpersistent users discontinued statin therapy after dispensation of the first prescription; of these, 42.1% did not recommence treatment within the following year. Factors reducing the likelihood of treatment discontinuation were older age (HR, 0.55; 95%CI, 039-0.77) and cotreatment with antihypertensive drugs (HR, 0.68; 95%CI, 0.56-0.82). No association was observed between treatment persistence and cotreatment with antidiabetic or antithrombotic drugs, baseline low-density lipoprotein levels, or total cholesterol levels. However, persistence was influenced by the type of statin first prescribed. Conclusions: Our analysis of a cohort of healthy male workers revealed poor statin persistence. These findings underscore the need for a better understanding of patterns of statin use, especially in apparently healthy individuals, and for the incorporation of patient behavior into prescribing decisions. (C) 2017 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:26 / 32
页数:7
相关论文
共 50 条
  • [41] Statins and Primary Prevention of Cardiovascular Disease in Women: A Critical Appraisal of the Evidence
    Ijioma, Nkechinyere
    Robinson, Jennifer G.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2015, 9 (02) : 114 - 129
  • [42] Determining optimal threshold for statins prescribing: individualization of statins treatment for primary prevention of cardiovascular disease
    Djulbegovic, Benjamin
    Tsalatsanis, Athanasios
    Hozo, Iztok
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2017, 23 (02) : 241 - 250
  • [43] 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
    Arnett, Donna K.
    Blumenthal, Roger S.
    Albert, Michelle A.
    Buroker, Andrew B.
    Goldberger, Zachary D.
    Hahn, Ellen J.
    Himmelfarb, Cheryl Dennison
    Khera, Amit
    Lloyd-Jones, Donald
    McEvoy, J. William
    Michos, Erin D.
    Miedema, Michael D.
    Munoz, Daniel
    Smith, Sidney C., Jr.
    Virani, Salim S.
    Williams, Kim A.
    Yeboah, Joseph
    Ziaeian, Boback
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (10) : E177 - U76
  • [44] Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France
    Giral, Philippe
    Neumann, Anke
    Weill, Alain
    Coste, Joel
    EUROPEAN HEART JOURNAL, 2019, 40 (43) : 3516 - 3525
  • [45] Statins for prevention of cardiovascular disease in systemic lupus erythematosus
    Yengej, F. A. Yousef
    Limper, M.
    Leavis, H. L.
    NETHERLANDS JOURNAL OF MEDICINE, 2017, 75 (03) : 99 - 105
  • [46] Lack of control of hypertension in primary cardiovascular disease prevention in Europe: Results from the EURIKA study
    Borghi, Claudio
    Tubach, Florence
    De Backer, Guy
    Dallongeville, Jean
    Guallar, Eliseo
    Medina, Jesus
    Perk, Joep
    Roy, Carine
    Banegas, Jose R.
    Rodriguez-Artalejo, Fernando
    Halcox, Julian P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 218 : 83 - 88
  • [47] Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis
    Major, Rupert W.
    Cheung, Chee Kay
    Gray, Laura J.
    Brunskill, Nigel J.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (05): : 732 - 739
  • [48] Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective
    Mahmood, D.
    Jahan, K.
    Habibullah, K.
    JOURNAL OF THE SAUDI HEART ASSOCIATION, 2015, 27 (03) : 179 - 191
  • [49] ; Primary prevention of cardiovascular diseases with statins in women
    Alici, Gokhan
    Karpuz, Vildan
    Karpuz, Hakan
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2009, 37 (04): : 273 - 280
  • [50] Primary Prevention of Cardiovascular Disease
    Eapen, Danny J.
    Schultz, William M.
    Heinl, Robert E.
    Ghasemzadeh, Nima
    Varghese, Tina
    Kurian, Diana E.
    Mathai, Christina E.
    Sandesara, Pratik
    Kindya, Bryan R.
    Allard-Ratick, Marc P.
    Bhatia, Neal K.
    Isiadinso, Ijeoma
    Sperling, Laurence
    CARDIOVASCULAR INNOVATIONS AND APPLICATIONS, 2016, 1 (04) : 379 - 389